NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
IYUZEH (latanoprost ophthalmic solution 0.005%) by Thea Pharma. Approved for prostaglandin analog [epc]. First approved in 2022.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IYUZEH is a prostaglandin analog ophthalmic solution (latanoprost 0.005%) approved in December 2022 for reducing intraocular pressure in glaucoma and ocular hypertension patients. It works by enhancing uveoscleral outflow of aquatic humor through prostaglandin receptor agonism. IYUZEH represents Thea Pharma's entry into the competitive prostaglandin analog market with a differentiated formulation.
$0.252MPart D
Peak4.8 years to LOEEarly-stage peak lifecycle with modest Part D uptake (572 claims) suggests product is still gaining traction; commercial team remains lean with growth opportunity ahead.
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on IYUZEH at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.